Specifically, CUR inhibits STAT3 phosphorylation and activation in lung cancer cells, leading to a 40%–60% reduction in tumor size and a significant decrease in the expression of STAT3 target genes such as cyclin D1, VEGF, MMP2, and MMP9. This evidence concerns the gene VEGFA and neoplasm.